Anixa reports positive Phase 1 breast cancer vaccine data; T-cell responses in 75% of patients

Anixa Biosciences Inc

16 TNBC patients treated; 12/16 (75%) developed antigen-specific T-cell responses at all dose levels.
Statistically significant increases in IFNγ (P=0.03) and IL-17 (P=0.0001) over baseline.
Dose Level 1 determined as immunologic and maximum tolerated dose; no serious adverse events besides injection site irritation.
Plans to evaluate vaccine with Keytruda in residual disease cohort and in BRCA/PALB2 mutation carriers.
CEO says data exceeded expectations; Phase 2/3 planning underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.